在初步诊断为广泛期SCLC时,18%的患者有脑转移且2年后增至约80%。EORTC(European Organization for Research and Treatment of Cancer)的一项研究,将对化疗有反应的患者随机化分为2组,接受PCI或不接受PCI,发现PCI治疗组1年生存率为27.1%,未接受PCI者为13.3%。[49]在该研究中,PCI不仅减少脑转移的发生率也提高无...
Treatment algorithm for small cell lung cancerNo Abstract available for this article.doi:10.1007/s00761-017-0215-9R. M. HuberLMU Klinikum der Universität München – Campus InnenstadtSpringer NatureDer Onkologe
Small-celllung cancer(SCLC) is a disease in which cells in your lung begin growing out of control. It starts in nerve cells or cells that make hormones. About 10% to 15% of lung cancer cases are small-cell. The other kind is called non-small-cell lung cancer. They’re different in ...
Treatment of relapse of small-cell lung cancer A relapse is when your cancer or the signs of it come back after improving for a while. If the disease doesn’t respond to treatment or gets worse after your initial treatment (called "refractory disease"), your doctor has other ways to ease...
small cell lung cancertreatmentAbstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. ...
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 23, 718–723 (2013). CAS PubMed Google Scholar Rudin, C. M. et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of...
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current...
Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. See the image below.
Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis. Most of the patients present with distant metastatic disease at the t